Novel Immunoregulatory Therapeutics for Systemic Lupus Erythematosus

系统性红斑狼疮的新型免疫调节疗法

基本信息

批准号：
10654040
负责人：
Andrew Leber
金额：
$ 56.37万
依托单位：
BIOTHERAPEUTICS, INC.
依托单位国家：
美国
项目类别：
财政年份：
2021
资助国家：
美国
起止时间：
2021-01-01 至 2024-06-30
项目状态：
已结题

来源：
https://reporter.nih.gov/project-details/10654040
关键词：
Abscisic Acid Acceleration Adoptive Transfer Adrenal Cortex Hormones Agonist American Ames Assay Animal Disease Models Anti-Inflammatory Agents Antinuclear Antibodies Autoimmune Autoimmune Diseases Autophagocytosis Biological Availability Biological Markers Biological Response Modifier Therapy Biotechnology Cardiovascular Diseases Chromosome abnormality Clinical Clinical Trials Combined Modality Therapy Computer Models Data Development Disease Dose Genetic Genetic Transcription Goals Health Care Costs Healthcare Histologic Histopathology Human IL8 gene Immune Immunosuppression Impairment In Vitro Inflammation Inflammatory Bowel Diseases Intercept Interleukin-2 Interleukin-6 Kidney Kidney Failure Kidney Transplantation Knowledge Lead Leadership Ligands Ligase Lupus Lupus Nephritis Marketing Mediating Metabolic Control Micronucleus Tests Modeling Mus Mutagenicity Tests Myeloid Cells No-Observed-Adverse-Effect Level Oral Organ Outcome Pathogenesis Pathway interactions Patients Peripheral Blood Mononuclear Cell Phagocytosis Pharmaceutical Preparations Phase Precision Health Predisposition Prednisone Preparation Program Development Proteinuria Quality of life RNA Rattus Regulatory Pathway Regulatory T-Lymphocyte Reporting Research Safety Sampling Serum Severity of illness Small Business Innovation Research Grant Systemic Lupus Erythematosus TLR7 gene TNF gene Target Populations Technology Therapeutic Toxic effect Treatment Efficacy Validation Whole Blood anti-dsDNA antibodies care burden chronic pain clinical development combinatorial commercial application commercialization comparative comparative efficacy drug development drug discovery ds-DNA effective therapy experience genetic signature genotoxicity healthy volunteer immune modulating agents immunoregulation improved interferon alpha receptor lanthionine mortality mouse model mycophenolate mofetil novel novel therapeutics precision medicine predictive signature public health relevance receptor resiquimod side effect standard of care therapeutically effective

项目摘要

Novel Immunoregulatory Drugs for Systemic Lupus Erythematosus BioTherapeutics, Inc (BTI) is an emerging biotech company that synergistically combines the power of advanced computational modeling with translational experimentation to accelerate the development of novel products for precision medicine and health. The company leadership has experience in advancing novel drugs from discovery to late-stage clinical development. Systemic lupus erythematosus (SLE) is an autoimmune disease that afflicts 1.5 million Americans. Through our previous research on abscisic acid, we discovered the anti-inflammatory and pro-regulatory immune effects of a novel class of oral lupus therapeutics. Our lead compound reduces key lupus biomarkers and overall disease severity in 3 mouse models and induces potent immunoregulatory effects in human PBMCs. This project will evaluate the comparative efficacy, safety and translatability of our novel agonists for the treatment of SLE. The Specific Aims for this SBIR Phase II application are to: (1) Evaluate the combinatorial and comparative efficacy of BT-96 in the NZB/W F1 model of SLE. NZB/W F1 mice will be therapeutically dosed with BT-96 at the maximally effective dose, independently or in combination with 5 standard-of-care or in-development drugs. Survival, anti-nuclear antibodies, proteinuria, and kidney histopathology will be assessed as endpoints. (2) Conduct IND-enabling genotoxicity and a 3-month repeat dose toxicity study in rats. We will perform an Ames test, chromosomal aberration study and micronucleus test to complete the FDA’s requirement for genetic toxicity. A 3-month toxicity study will be conducted to evaluate general safety. (3) Elucidate a translational signature of BT-96 to serve as a dose-ranging marker of target engagement. RNA samples from NZB/W F1 whole blood will be used to identify correlates between transcriptional changes and oral efficacy at various doses. Transcriptional changes will be aligned with mechanism of action and histological and biomarker results. Signature will be validated in SLE patient PBMCs. Expected successful outcomes will include: i) improved protection from proteinuria with BT-96 relative to other therapies; ii) NOAEL ≥ 500 mg/kg; and iii) validation of regulatory T cell and phagocytosis-mediated mechanisms. The long-term goal of this project is to develop a novel immunomodulatory therapeutic capable of serving as a safer and more effective treatment for SLE and provide a path towards commercialization of a product candidate with a target population of over 5 million resulting in a market of over $1.5 billion.

全身性红斑狼疮的新型免疫调节药物 Biotherapeutics，Inc（BTI）是一家新兴的生物技术公司，协同结合了其力量通过翻译实验的高级计算建模，以加速新型精确医学和健康的产品。公司领导有发展新型毒品的经验从发现到晚期临床开发。全身性红斑狼疮（SLE）是一种折磨150万美国人的自身免疫性疾病。通过我们的先前关于脱落酸的研究，我们发现新型口服狼疮疗法。我们的铅化合物减少了关键的狼疮生物标志物和整体疾病在3种小鼠模型中的严重程度，并在人PBMC中诱导潜在的免疫调节作用。这个项目将评估我们的新型激动剂对SLE治疗的比较效率，安全性和可翻译性。 SBIR II期应用的具体目的是：（1）评估BT-96在SLE的NZB/W F1模型中的组合和比较效率。 NZB/w F1小鼠将独立或组合以最大有效剂量为BT-96热涂料使用5种护理标准或开发药物。生存，抗核抗体，蛋白尿和肾脏组织病理学将被评估为终点。（2）在大鼠中进行指成遗传毒性和3个月重复剂量毒性研究。我们将表演 AMES测试，染色体畸变研究和微核测试，以完成FDA的要求遗传毒性。将进行3个月的毒性研究以评估一般安全性。（3）阐明BT-96的翻译签名作为目标参与的剂量范围标记。 NZB/W F1全血的RNA样品将用于识别转录变化之间的相关性和口服效率各种剂量。转录变化将与作用机理和组织学和生物标志物结果。签名将在SLE患者PBMC中进行验证。预期的成功结果将包括：i）改善与其他BT-96相对于其他BT-96的蛋白尿的保护疗法； ii）Noael≥500mg/kg; iii）验证调节性T细胞和吞噬作用介导的机制。该项目的长期目标是开发一种新型的免疫调节治疗，能够充当 SLE的更安全，更有效的治疗方法，并为候选产品的商业化提供了途径目标人口超过500万，市场超过15亿美元。